Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

Film body questions Diljit Dosanjh's casting in Border 2, writes open letter The weight loss drug market has gotten messy. What to know. Berkshire Hathaway Class A stock is selling at a discount.

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Novo Nordisk launched its blockbuster weight loss drug Wegovy (Semaglutide) in India on Tuesday, ahead of a patent expiry next year, which will see generic versions flooding the Indian market ...

STEP UP co-primary endpointsat 72 weeks *1: semaglutide 7.2 mg semaglutide 2.4 mg Placebo Weight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of ...

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7%, compared to 17.5% with the lower dose and 2.4% in the placebo group.

Advocacy for wider access to semaglutide. Although semaglutide is available in Australia for other conditions, it is not yet listed on the Pharmaceutical Benefits Scheme (PBS) for weight loss.